Olezarsen · Tryngolza

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Hypertriglyceridemia · Phase 3 · investigational in the US

Also approved (2)
CA
  • Adjunct to diet in adult patients for the treatment of FCS (Notice of Compliance date from the CDA-AMC review; sponsor Theratechnologies Inc.)
Product first approved 2025canjhealthtechnol.ca
EU
  • Adjunct to diet in adults with genetically confirmed familial chylomicronemia syndrome; marketing authorisation holder Swedish Orphan Biovitrum AB (Sobi)
Product first approved 2025EMA

Company guidance: regulatory decision expected fourth quarter of 2026 (Ionis Pharmaceuticals, 9 Nov 2026). “FCS launch outside the U.S. underway; received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for sHTG (sHTG fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]), paving the way to bring TRYNGOLZA to sHTG patients across Europe with a final approval decision expected in the fourth quarter of 2026” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Familial Chylomicronemia Syndrome
NCT07727538 · Ionis Pharmaceuticals, Inc.
2026-07-31 – 2031-08 · Familial Chylomicronemia Syndrome
What this study did
NCT05130450 · Ionis Pharmaceuticals, Inc.
2021-11-18 – 2028-02 · Familial Chylomicronemia Syndrome
What this study did
NCT05185843 · Ionis Pharmaceuticals, Inc.
2022-02-25 – 2027-06 · Familial Chylomicronemia Syndrome
What this study did
Severe Hypertriglyceridemia
NCT05681351 · Ionis Pharmaceuticals, Inc.
2022-12-13 – 2027-03 · Severe Hypertriglyceridemia
What this study did
Phase 2 (2)
Hypertriglyceridemia
NCT03385239 · Akcea Therapeutics
2018-01-30 – 2020-02-25 · Hypertriglyceridemia, Cardiovascular Diseases
What this study did
Severe Hypertriglyceridemia
NCT05355402 · Ionis Pharmaceuticals, Inc.
2022-05-09 – 2023-12-21 · Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
What this study did
Phase 1 (2)
Other / comorbidity
NCT05579860 · Ionis Pharmaceuticals, Inc.
2022-10-05 – 2023-05-22 · Healthy Participants
What this study did
NCT02900027 · Ionis Pharmaceuticals, Inc.
2016-09 – 2018-04-30 · Elevated Triglycerides (TG)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Severe Hypertriglyceridemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Olezarsen (Tryngolza): this drugApprovedRNA / oligonucleotideAPOC3Reliable signal
NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001)
NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001).
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3)
Omega-3-Acid Ethyl Esters (Lovaza)ApprovedSmall moleculeTriglyceride metabolismnot yet gradedNo reviewed efficacy summary in this indication
Omega-3-Acid Ethyl Esters A (Omtryg)
ApprovedUS marketing discontinued
Small moleculeTriglyceride synthesis / VLDLnot yet gradedNo reviewed efficacy summary in this indication
DR10624Phase 3Protein / enzyme therapeuticGLP-1R; GCGR; FGF21RPartial signal
NCT06555640: Median triglyceride reduction: 74.5% (12.5 mg), 66.2% (25 mg), 68.9% (50 mg titration) vs 8.0% with placebo
PegozaferminPhase 3Protein / enzyme therapeuticFGFR1c/2c/3c–β-Klotho agonistPartial signalNo reviewed efficacy summary in this indication
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signal
NCT03011450: Percent Change in Fasting TG From Baseline to Week 12 (12 Weeks): K-877 -58.89% (IQR -71.69 to -38.42) vs Placebo -22.94% (IQR -43.98 to 9.67)
NCT03001817: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 (12 Weeks): K-877 -56% (IQR -72.08 to -32.4) vs Placebo -7.97% (IQR -44.78 to 49.87)
Plozasiran (Redemplo)Phase 3RNA / oligonucleotideAPOC3Partial signalNo reviewed efficacy summary in this indication
Volanesorsen (Waylivra)Phase 3RNA / oligonucleotideAPOC3 mRNAPartial signal
NCT02300233: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Volanesorsen Total -71.2% (95% CI -79.3 to -63.2) vs Placebo -0.9% (95% CI -13.9 to 12.2)
HRS-7249Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
ION775Phase 2RNA / oligonucleotideAPOC3not yet gradedNo reviewed efficacy summary in this indication
SEFA-1024
Phase 2(overall)
Small moleculeHepatic triglyceride/VLDL synthesis pathwayPartial signalNo reviewed efficacy summary in this indication
SolbinsiranPhase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
CS-121Phase 1Gene therapy / editingAPOC3not yet gradedNo reviewed efficacy summary in this indication
CTX310Phase 1Gene therapy / editingANGPTL3not yet gradedNo reviewed efficacy summary in this indication
GC304
Phase 1(overall)
Gene or cell therapy (subtype unspecified)LPL (lipoprotein lipase) genenot yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tryngolza (Olezarsen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 3Severe HypertriglyceridemiaActive not recruiting
Est. primary completion 2027-03 · NCT05681351 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Familial Chylomicronemia SyndromeActive not recruiting
Est. primary completion 2027-06 · NCT05185843 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 3Familial Chylomicronemia SyndromeActive not recruiting
Est. primary completion 2028-02 · NCT05130450 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 3Familial Chylomicronemia SyndromeRecruiting
Est. primary completion 2030-08 · NCT07727538 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalEuropean Commission approves Tryngolza in severe hypertriglyceridaemia
EU, European Commission · Source ↗
19 May 2025Topline resultPhase 3 Essence (NCT05610280) of olezarsen met its primary endpoint
Ionis Pharmaceuticals · Source ↗